Greenland Resources ships Malmbjerg core and saline water to SGS for magnesium, rare earths test program
Bitget2026/10/06 13:57Greenland Resources launched lab and pilot testwork to assess magnesium and rare earth by-product recovery at its Malmbjerg project. Program backed by CAD 7 million from Natural Resources Canada to test molybdenum flotation using fresh water versus saline water. About 8 tonnes of drill core, 12 tonnes of saline water, and 2 tonnes of fresh water were collected for the work. Materials are due at SGS Lakefield, Ontario around Oct. 12; testing is scheduled to run through March 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greenland Resources Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610060957BIZWIRE_USPR_____20261006_BW358084) on October 06, 2026, and is solely responsible for the information contained therein.
- Greenland Resources launched lab and pilot testwork to assess magnesium and rare earth by-product recovery at its Malmbjerg project.
- Program backed by CAD 7 million from Natural Resources Canada to test molybdenum flotation using fresh water versus saline water.
- About 8 tonnes of drill core, 12 tonnes of saline water, and 2 tonnes of fresh water were collected for the work.
- Materials are due at SGS Lakefield, Ontario around Oct. 12; testing is scheduled to run through March 2028.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley raises CME Group price target to $337
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.